These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37957370)

  • 21. PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma.
    Ping L; Gao Y; He Y; Bai B; Huang C; Shi L; Wang X; Huang H
    Ann Hematol; 2023 Aug; 102(8):2189-2198. PubMed ID: 37306710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
    Westin J; Davis RE; Feng L; Hagemeister F; Steiner R; Lee HJ; Fayad L; Nastoupil L; Ahmed S; Rodriguez A; Fanale M; Samaniego F; Iyer SP; Nair R; Oki Y; Fowler N; Wang M; Ma MCJ; Vega F; McDonnell T; Pinnix C; Griffith D; Lu Y; Tewari S; Sun R; Scott DW; Flowers CR; Neelapu S; Green MR
    J Clin Oncol; 2023 Feb; 41(4):745-755. PubMed ID: 35952327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma.
    Wang X; Yu L; Jiang X; Ding K
    Cancer Med; 2023 May; 12(9):10553-10562. PubMed ID: 36912128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
    Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
    Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
    Palazón-Carrión N; Martín García-Sancho A; Nogales-Fernández E; Jiménez-Cortegana C; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Salar-Silvestre A; Rodríguez-Abreu D; Gálvez-Carvajal L; Labrador J; Guirado-Risueño M; García-Domínguez DJ; Hontecillas-Prieto L; Espejo-García P; Fernández-Román I; Provencio-Pulla M; Sánchez-Beato M; Navarro M; Marylene L; Álvaro-Naranjo T; Casanova-Espinosa M; Sánchez-Margalet V; Rueda-Domínguez A; de la Cruz-Merino L
    Clin Cancer Res; 2022 Sep; 28(17):3658-3668. PubMed ID: 35727601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
    Zinzani PL; Pellegrini C; Gandolfi L; Stefoni V; Quirini F; Derenzini E; Broccoli A; Argnani L; Pileri S; Baccarani M
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):462-6. PubMed ID: 21859554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
    Nowakowski GS; Chiappella A; Gascoyne RD; Scott DW; Zhang Q; Jurczak W; Özcan M; Hong X; Zhu J; Jin J; Belada D; Bergua JM; Piazza F; Mócikova H; Molinari AL; Yoon DH; Cavallo F; Tani M; Yamamoto K; Izutsu K; Kato K; Czuczman M; Hersey S; Kilcoyne A; Russo J; Hudak K; Zhang J; Wade S; Witzig TE; Vitolo U
    J Clin Oncol; 2021 Apr; 39(12):1317-1328. PubMed ID: 33621109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
    Cox MC; Pelliccia S; Marcheselli L; Battistini R; Arcari A; Borza PA; Patti C; Casaroli I; di Landro F; Di Napoli A; Fabbri F; Caridi M; Tafuri A; Bocci G; Musuraca G
    Invest New Drugs; 2019 Jun; 37(3):548-558. PubMed ID: 31028663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
    Feldman T; Mato AR; Chow KF; Protomastro EA; Yannotti KM; Bhattacharyya P; Yang X; Donato ML; Rowley SD; Carini C; Valentinetti M; Smith J; Gadaleta G; Bejot C; Stives S; Timberg M; Kdiry S; Pecora AL; Beaven AW; Goy A
    Br J Haematol; 2014 Jul; 166(1):77-83. PubMed ID: 24661044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
    Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
    Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis.
    Ip A; Mutebi A; Wang T; Jun M; Kalsekar A; Navarro FR; Wang A; Kamalakar R; Sacchi M; Elliott B
    Adv Ther; 2024 Mar; 41(3):1226-1244. PubMed ID: 38302846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
    Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M
    Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
    Noel R; Zemmour C; Montes de Oca C; Belmecheri N; Aurran-Schleinitz T; Coso D; Lopez Almeida L; Mescam L; Vey N; Bladé JS; Slama B; Bouabdallah R; Schiano de Colella JM
    Hematology; 2023 Dec; 28(1):2207948. PubMed ID: 37133334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of polatuzumab-bendamustine-rituximab
    Calamia M; McBride A; Abraham I
    J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
    Oberic L; Peyrade F; Puyade M; Bonnet C; Dartigues-Cuillères P; Fabiani B; Ruminy P; Maisonneuve H; Abraham J; Thieblemont C; Feugier P; Salles G; Bijou F; Pica GM; Damaj G; Haioun C; Casasnovas RO; Farhat H; Le Calloch R; Waultier-Rascalou A; Malak S; Paget J; Gat E; Tilly H; Jardin F
    J Clin Oncol; 2021 Apr; 39(11):1203-1213. PubMed ID: 33444079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients.
    Qin Y; He X; Chen X; Xie Z; Yang J; Yang S; Liu P; Zhou S; Zhang C; Gui L; Shi Y
    Eur J Haematol; 2023 Sep; 111(3):356-364. PubMed ID: 37294015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
    Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
    Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
    Nowakowski GS; Yoon DH; Peters A; Mondello P; Joffe E; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Huang D; Waltl EE; Winderlich M; Kurukulasuriya NC; Ambarkhane S; Hess G; Salles G
    Clin Cancer Res; 2022 Sep; 28(18):4003-4017. PubMed ID: 35674661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.